|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
2
|
Schröder FH, Hugosson J, Roobol MJ, et al:
Screening and prostate cancer mortality in a randomized European
study. N Engl J Med. 360:1320–1328. 2009.PubMed/NCBI
|
|
3
|
Fornaro M, Manes T and Languino LR:
Integrins and prostate cancer metastases. Cancer Metastasis.
20:321–331. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Devlin HL and Mudryj M: Progression of
prostate cancer: multiple pathways to androgen independence. Cancer
Lett. 274:177–186. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
US Preventive Services Task Force.
Screening for prostate cancer: US Preventive Services Task Force
recommendation statement. Ann Intern Med. 149:185–191. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Crawford ED and Abrahamsson PA: PSA-based
screening for prostate cancer: how does it compare with other
cancer screening tests? Eur Urol. 54:262–273. 2008. View Article : Google Scholar
|
|
7
|
McGregor M, Hanley JA, Boivin JF and
McLean RG: Screening for prostate cancer: estimating the magnitude
of overdetection. CMAJ. 159:1368–1372. 1998.PubMed/NCBI
|
|
8
|
Liu AY, Roudier MP and True LD:
Heterogeneity in primary and metastatic prostate cancer as defined
by cell surface CD profile. Am J Pathol. 165:1543–1556. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Recker F, Kwiatkowski MK, Piironen T,
Pettersson K, Gorpel M and Tscholl R: Free-to-total prostate
specific antigen (PSA) improves the specificity for detecting
prostate cancer in patients with prostatism and intermediate PSA
levels. Br J Urol. 81:532–538. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Benson MC, Whang IS, Pantuck A, Ring K,
Kaplan SA, Olsson CA and Cooner WH: Prostate specific antigen
density: a means of distinguishing benign prostatic hypertrophy and
prostate cancer. J Urol. 147:815–816. 1992.PubMed/NCBI
|
|
11
|
Catalona WJ, Richie JP, deKernion JB, et
al: Comparison of prostate specific antigen concentration versus
prostate specific antigen density in the early detection of
prostate cancer: receiver operating characteristic curves. J Urol.
152:2031–2036. 1994.
|
|
12
|
Smith DS and Catalona WJ: Rate of change
in serum prostate specific antigen levels as a method for prostate
cancer detection. J Urol. 152:1163–1167. 1994.PubMed/NCBI
|
|
13
|
Lein M, Kwiatkowski M, Semjonow A, et al:
A multicenter clinical trial on the use of complexed prostate
specific antigen in low prostate specific antigen concentrations. J
Urol. 170:1175–1179. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mikolajczyk SD and Rittenhouse HG:
Tumor-associated forms of prostate specific antigen improve the
discrimination of prostate cancer from benign disease. Rinsho
Byori. 52:223–230. 2004.PubMed/NCBI
|
|
15
|
Seiz L, Kotzsch M, Grebenchtchikov NI, et
al: Polyclonal antibodies against kallikrein-related peptidase 4
(KLK4): immunohistochemical assessment of KLK4 expression in
healthy tissues and prostate cancer. Biol Chem. 391:391–401. 2010.
View Article : Google Scholar
|
|
16
|
Zhou H-J, Yan J, Luo W, et al: SRC-3 is
required for prostate cancer cell proliferation and survival.
Cancer Res. 65:7976–7983. 2005.PubMed/NCBI
|
|
17
|
Fizazi K: The role of Src in prostate
cancer. Ann Oncol. 18:1765–1773. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang CS, Kokontis J and Liao ST:
Structural analysis of complementary DNA and amino acid sequences
of human and rat androgen receptors. Proc Natl Acad Sci USA.
85:7211–7215. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hsing AW, Chokkalingam AP, Gao YT, et al:
Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and
prostate cancer risk: a population base case control study. Cancer
Epidemiol Biomarkers Prev. 11:337–341. 2002.PubMed/NCBI
|
|
20
|
Padmanabhan V, Callas P, Philips G,
Trainer TD and Beatty BG: DNA replication regulation protein Mcm7
as a marker of proliferation in prostate cancer. J Clin Pathol.
57:1057–1062. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dudderidge TJ, Kelly JD, Wollenschlaeger
A, et al: Diagnosis of prostate cancer by detection of
minichromosome maintenance 5 protein in urine sediments. Br J
Cancer. 103:701–707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rennebeck G, Martelli M and Kyprianou N:
Anoikis and survival connections in the tumor microenvironment: is
there a role is prostate cancer metastasis? Cancer Res.
65:11230–11235. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kuefer R, Hofer MD, Zorn CS, et al:
Assessment of a fragment of e-cadherin as a serum biomarker with
predictive value for prostate cancer. Br J Cancer. 92:2018–2023.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tomita K, van Bokhoven A, van Leenders GJ,
et al: Cadherin switching in human prostate cancer progression.
Cancer Res. 60:3650–3654. 2000.PubMed/NCBI
|
|
25
|
Mao Q, Zheng X, Yang K, et al: Suppression
of migration and invasion of PC3 prostate cancer cell line via
activating E-cadherin expression by small activating RNA. Cancer
Invest. 28:1013–1018. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Partin AW, Getzenberg RH and CarMichael
MJ: Nuclear matrix protein patterns in human benign prostatic
hyperplasia and prostate cancer. Cancer Res. 53:744–746.
1993.PubMed/NCBI
|
|
27
|
Leman ES, Magheli A, Cannon GW, Mangold L,
Partin AW and Getzenberg RH: Analysis of a serum test for prostate
cancer that detects a second epitope of EPCA-2. Prostate.
69:1188–1194. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shariat SF, Karam JA, Walz J, et al:
Improved prediction of disease relapse after radical prostatectomy
through a panel of preoperative blood-based biomarkers. Clin Cancer
Res. 14:3785–3791. 2008. View Article : Google Scholar
|
|
29
|
Malinowska K, Neuwirt H, Cavaretta IT, et
al: Interleukin-6 stimulation of growth of prostate cancer in
vitro and in vivo through activation of the androgen
receptor. Endocr Relat Cancer. 16:155–169. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Santer FR, Malinowska K, Culig Z and
Cavarretta IT: Interleukin-6 trans-signaling regulates
proliferation, migration, adhesion, and maspin expression in human
prostate cancer cells. Endocr Relat Cancer. 17:241–253. 2010.
View Article : Google Scholar
|
|
31
|
Hessels D, van Gils MP, van Hooij O,
Jannink SA, Witjes JA, Verhaegh GW and Schalken JA: Predictive
value of PCA3 in urinary sediments in determining
clinico-pathological characteristics of prostate cancer. Prostate.
70:10–16. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Groskopf J, Aubin SM, Deras IL, et al:
APTIMA PCA3 molecular using test: development of a method to aid in
the diagnosis of prostate cancer. Clin Chem. 52:1089–1095. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Roobol MJ, Schröder FH, van Leeuwen P,
Wolters T, van den Bergh RC, van Leenders GJ and Hessels D:
Performance of the prostate cancer antigen 3 (PCA3) gene and
prostate specific antigen in prescreen men: exploring the value of
PCA3 for a first line diagnostic test. Eur Urol. 58:475–481. 2010.
View Article : Google Scholar
|
|
34
|
Helenius MA, Savinainen KJ, Bova GS and
Visakorpi T: Amplification of the urokinase gene and the
sensitivity of prostate cancer cells to urokinase inhibitor. BJU
Int. 97:404–409. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Varambally S, Dhanasekaran SM, Zhou M, et
al: The polycomb group protein EZH2 is involved in progression of
prostate cancer. Nature. 419:624–629. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Laitinen S, Martikainen PM, Tolonen T,
Isola J, Tammela TL and Visakorpi T: EZH2, Ki-67, and Mcm7 are
prognostic markers in prostatectomy treated patients. Int J Cancer.
122:595–602. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li J, Fan QH, Fan XS, Zhou W, Qiu Y and
Qiu L: EZH2 expression in human prostate cacner and its
clinicopathologic significance. Zhonghua Nan Ke Xue. 16:123–128.
2010.(In Chinese).
|
|
38
|
Yu J, Yu J, Mani RS, et al: An integrated
network of androgen receptor, polycomb, and TMPRSS2-ERG gene
fusions in prostate cancer progression. Cancer Cell. 17:443–454.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yu J, Cao Q, Yu J, et al: The neuronal
repellant SLIT2 is a target for repression by EZH2 in prostate
cancer. Oncogene. 29:5370–5380. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cao P, Deng Z, Wan M, et al: MicroRNA-101
negtively regulates EZH2 and its expression is modulated by
androgen receptor HIF-1α/HIF-1β. Mol Cancer. 9:1082010.PubMed/NCBI
|
|
41
|
Gu Z, Thomas G, Yamashiro J, et al:
Prostate stem cell antigen (PSCA) expression increases with high
gleason score, advanced stage and bone metastasis in prostate
cancer. Oncogene. 19:1288–1296. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhao Z, Liu J, Li S and Shen W: Prostate
stem cell antigen mRNA expression in preoperatively negative biopsy
specimens predicts subsequent cancer after transurethral resection
of the prostate for benign prostatic hyperplasia. Prostate.
69:1292–1302. 2009. View Article : Google Scholar
|
|
43
|
Linja MJ, Savinainen KJ, Saramaki OR,
Tammela TL, Vessella RL and Visakorpi T: Amplification and
overexpression of androgen receptor gene in hormone refractory
prostate cancer. Cancer Res. 61:3550–3555. 2001.PubMed/NCBI
|
|
44
|
Sun S, Sprenger CC, Vessella RL, et al:
Castration resistance in human prostate cancer is conferred by a
frequently occurring androgen receptor splice variant. J Clin
Invest. 120:2715–2730. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dahlman A, Edsjö A, Halldén C, et al:
Effect of androgen deprivation therapy on the expression of
prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.
Prostate Cancer Prostatic Dis. 13:369–375. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Swinnen JV, Roskams T, Joniau S, et al:
Overexpression of fatty acid synthase is an early and common event
in the development of prostate cancer. Int J Cancer. 98:19–22.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Rossi S, Graner E, Febbo P, et al: Fatty
acid synthase expression defines distinct molecular signatures in
prostate cancer. Mol Cancer Res. 1:707–715. 2003.PubMed/NCBI
|
|
48
|
Kristiansen G, Fritzsche FR, Wasserman K,
et al: GOLPH2 protein expression as a novel tissue biomarker for
prostate cancer: implications for tissue-based diagnostics. Br J
Cancer. 99:939–948. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Laxman B, Morris DS, Yu J, et al: A
first-generation multiplex biomarker analysis of urine for the
early detection of prostate cancer. Cancer Res. 68:645–649. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Morgan R, Boxall A, Bhatt A, et al:
Engrailed-2 (EN2): a tumor specific urinary biomarker for the early
diagnosis of prostate cancer. Clin Cancer Res. 17:1090–1098. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hermans KG, van Marion R, van Dekken H,
Jenster G, van Weerden WM and Trapman J: TMPRSS2:ERG fusion by
translocation or interstitial deletion is highly relevant in
androgen-dependent prostate cancer, but is bypassed in late-stage
andgrogen receptor-negative prostate cancer. Cancer Res.
66:10658–10663. 2006. View Article : Google Scholar
|
|
52
|
Perner S, Demichelis F, Beroukhim R, et
al: TMPRSS2:ERG fusion associated deletions provide insight into
the heterogeneity of prostate cancer. Cancer Res. 66:8337–8341.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Soller MJ, Isaksson M, Elfving P, Soller
W, Lundgren R and Panagopoulos I: Confirmation of the high
frequency of the TMPRSS2:ERG fusion gene in prostate cancer. Genes
Chromosomes Cancer. 45:717–719. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Nam RK, Sugar L, Wang Z, et al: Expression
of TMPRSS2:ERG gene fusions in prostate cancer cells is an
important prognostic factor for cancer progression. Cancer Biol
Ther. 6:40–45. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Rajput AB, Miller MA, De Luca A, et al:
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate
to poorly differentiated prostate cancers. J Clin Pathol.
60:1238–1243. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Tu JJ, Rohan S, Kao J, Kitabayashi N,
Mathew S and Chen YT: Gene fusions between TMPRSS2 and ETS family
genes in prostate cancer: frequency and transcript variant analysis
by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol.
20:921–928. 2007. View Article : Google Scholar
|
|
57
|
Narod SA, Seth A and Nam R: Fusion in the
ETS gene family and prostate cancer. Br J Cancer. 99:847–851. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Demichelis F, Fall K, Perner S, et al:
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a
watchful waiting cohort. Oncogene. 26:4569–4599. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Barwick BG, Abramovitz M, Kodani M, et al:
Prostate cancer genes associated with TMPRSS2-ERG gene fusion and
prognostic of biochemical recurrence in multiple cohorts. Br J
Cancer. 102:570–576. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Stenman UH: SPINK1: a new therapeutic
target in cancer? Clin Chem. 57:1474–1475. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Goldstein AS, Zong Y and Witte ON: A two
step toward personalized therapies for prostate cancer. Sci Transl
Med. 3:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Tomlins SA, Rhodes DR, Yu J, et al: The
role of SPINK1 in ETS rearrangement negative prostate cancer.
Cancer Cell. 13:519–528. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Bibikova M, Chudin E, Arsanjani A, et al:
Expression signatures that correlated with Gleason score and
relapse in prostate cancer. Genomics. 89:666–672. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Phé V, Cussenot O and Rouprêt M:
Methylated genes as potential biomarkers in prostate cancer. BJU
Int. 105:1364–1370. 2010.
|
|
65
|
Woodson K, O’Reilly KJ, Hanson JC, Nelson
D, Walk EL and Tangrea JA: The usefulness of the detection of GSTP1
methylation in urine as a biomarker in the diagnosis of prostate
cancer. J Urol. 179:508–512. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Lou H, Yeager M, Li H, et al: Fine mapping
and functional analysis of a common variant in MSMB on chromosome
10q11.2 associated with prostate cancer susceptibility. Proc Natl
Acad Sci USA. 106:7933–7938. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Ahn J, Kibel AS, Park JY, et al: Prostate
cancer predisposition loci and risk of metastatic disease and
prostate cancer recurrence. Clin Cancer Res. 17:1075–1081. 2011.
View Article : Google Scholar : PubMed/NCBI
|
